Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 1:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 61 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Testim, 1% testosterone gel Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

NCT02513940
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Testosterone, Progesterone, Placebo, Ibutilide
Drug
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 4, 2026, 1:17 PM EDT
Terminated Early Phase 1 Interventional Results available

Testosterone for Penile Rehabilitation After Radical Prostatectomy

NCT00848497
View directory record Official record
Conditions
Hypogonadism, Erectile Dysfunction
Interventions
Testim®, Placebo Testim®, Viagra®
Drug · Other
Lead sponsor
Mohit Khera
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 4, 2026, 1:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Testosterone on Prostate Tissue (ACYP-1)

NCT00161486
View directory record Official record
Conditions
Hypogonadism, Contraception
Interventions
Testosterone gel, Acyline, Placebo acyline, Placebo Testosterone gel
Drug
Lead sponsor
University of Washington
Other
Eligibility
35 Years to 55 Years · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2008 · Synced Oct 4, 2026, 1:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NES Gel-1, To Evaluate Nestorone Gel in Combination With Testosterone Gel

NCT00229593
View directory record Official record
Conditions
Contraception
Interventions
Nestorone gel, Testosterone Gel
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 4, 2026, 1:17 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism

NCT00467987
View directory record Official record
Conditions
Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism
Interventions
androgel, placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
31 Years to 60 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 4, 2026, 1:17 PM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions

NCT02110368
View directory record Official record
Conditions
Primary Hypogonadism, Hypogonadotropic Hypogonadism
Interventions
Testosterone Topical Gel, 1.62% Metered Pump, AndroGel (testosterone gel) 1.62% Metered-Dose Pump
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 4, 2026, 1:17 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Regulation of Cortisol Metabolism and Fat Patterning

NCT00694733
View directory record Official record
Conditions
Obesity, Menopausal Syndrome
Interventions
Placebo injection, Depo Lupron/Aromatase inhibitor, Depo Lupron/placebo, placebo, Estrogen cream
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 62 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Oct 4, 2026, 1:17 PM EDT
Completed Phase 3 Interventional

Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

NCT01235754
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
transdermal testosterone gel 1%, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 66 Years · Female only
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
98
States / cities
Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 4, 2026, 1:17 PM EDT
Completed Phase 4 Interventional

Natesto Spermatogenesis Reboot

NCT05381831
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
NatestoTM
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 64 Years · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 4, 2026, 1:17 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

NCT00657501
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
66
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 4, 2026, 1:17 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

ITT4 Intratesticular Hormonal Milieu in Man (ITT4)

NCT01215292
View directory record Official record
Conditions
Healthy Males
Interventions
Acyline, Testosterone gel, ketoconazole 400, Ketoconazole 800, Dutasteride, Anastrozole, Placebo ketoconazole
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 4, 2026, 1:17 PM EDT
Terminated Phase 4 Interventional Results available

TOM: Testosterone in Older Men With Sarcopenia

NCT00240981
View directory record Official record
Conditions
Sarcopenia, Hypogonadism, Muscular Diseases
Interventions
Topical testosterone gel 1% (active formulation), Topical gel (placebo formulation)
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
65 Years and older · Male only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 4, 2026, 1:17 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone (HOP 5) Testicular Aspiration Addendum

NCT00156650
View directory record Official record
Conditions
Contraception
Interventions
Acyline, Testosterone Gel, Depo-Medroxyprogesterone
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2008 · Synced Oct 4, 2026, 1:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men

NCT00957801
View directory record Official record
Conditions
Sarcopenia
Interventions
Testosterone injection, Testosterone gel, Medrol
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years to 85 Years · Male only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 4, 2026, 1:17 PM EDT
Completed Phase 2 Interventional Results available

To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone

NCT00706719
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
25 mg Androxal, Testim 1%
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
21 Years to 60 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
New York, New York • Purchase, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 4, 2026, 1:17 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

ITT-5 Mechanisms of Spermatogenesis in Man

NCT02147964
View directory record Official record
Conditions
Gonadotropin Deficiency
Interventions
Testosterone 1% Gel, Acyline, Dutasteride, Ketoconazole, HCG, placebo dutasteride, placebo ketoconazole
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 4, 2026, 1:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluate the Pharmacokinetics and Gonadotropin Suppression of Nestorone®-Testosterone (NES/T) Combination Gel in Men

NCT02432261
View directory record Official record
Conditions
Healthy
Interventions
Nestorone® /testosterone gel, Testosterone only gel
Drug
Lead sponsor
Kimberly Myer
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 4, 2026, 1:17 PM EDT
Completed Not applicable Interventional Results available

Testosterone Replacement Therapy in Advanced Chronic Kidney Disease

NCT00645658
View directory record Official record
Conditions
Kidney Failure, Kidney Diseases
Interventions
Testim, 1% testosterone gel
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Palo Alto, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 4, 2026, 1:17 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo

NCT04807894
View directory record Official record
Conditions
Recurrent Urinary Tract Infection, Vaginal Atrophy, Postmenopausal Disorder
Interventions
Vaginal Cream with Applicator
Drug
Lead sponsor
Jefferson Drapkin
Other
Eligibility
60 Years to 90 Years · Female only
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 4, 2026, 1:17 PM EDT
Terminated Phase 2 Interventional Results available

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

NCT00515112
View directory record Official record
Conditions
Prostate Cancer
Interventions
AndroGel, placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 4, 2026, 1:17 PM EDT
Terminated Phase 1 Interventional

Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome

NCT00438321
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Zoladex, Testosterone gel, Anastrozole Pill, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years to 75 Years · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 4, 2026, 1:17 PM EDT
Completed Phase 4 Interventional

Vogelxo(R) ABPM Study in Hypogandal Men

NCT04558567
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
Vogelxo
Drug
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Anaheim, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 4, 2026, 1:17 PM EDT
Completed Phase 2 Interventional Results available

Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

NCT00586898
View directory record Official record
Conditions
Prostate, Cancer, Hormonal Cycling
Interventions
GnRH, Ketoconazole, Bicalutamide, Testosterone transdermal gel, Estrogen transdermal patch
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2016 · Synced Oct 4, 2026, 1:17 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

NCT06084338
View directory record Official record
Conditions
Prostate Cancer
Interventions
stereotactic ablative radiotherapy, Pluvicto, topical testosterone
Radiation · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
4
States / cities
West Los Angeles, California • Hines, Illinois • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 4, 2026, 1:17 PM EDT